9 results about "Cholesterol absorption" patented technology

The application relates to the field of biological medicine, in particular to application of TDF in serum cholesterol regulation and a verification method. The application discloses that tenofovir disoproxil fumarate (TDF) can inhibit intestinal cholesterol absorption by specifically down-regulating the expression level of NPC1L1 protein in the intestinal tract, so as to reduce serum cholesterol. The regulation has tissue specificity, and TDF has no significant influence on the expression of key genes of liver cholesterol metabolism. The application also provides a method for verifying the regulation of TDF on serum cholesterol, which is evaluated by detecting blood lipid indexes and the gene and / or protein expression level of NPC1L1 in duodenal tissue. The application provides a treatment scheme with antiviral and cholesterol-lowering effects for patients with chronic hepatitis B combined with hypercholesterolemia, and provides a new idea for developing a lipid-lowering strategy targeting intestinal cholesterol absorption.

[Problem] To provide a composition that is improved in cholesterol-absorption-inhibitory action of pea protein, and to provide a method for producing said composition. Additionally, to provide a method for improving the cholesterol-absorption-inhibitory action of pea protein. [Solution] The aforementioned problem is solved by a composition for inhibiting cholesterol absorption, the composition containing pea protein having a particle diameter of 180 μm or less as an active ingredient. Preferably, a food, a beverage, a medicine, or a feed contains the composition for inhibiting cholesterol absorption. Also provided is a method for producing a composition for inhibiting cholesterol absorption, the method comprising a step for refining the particle diameter of pea protein. Furthermore provided is a method for improving the cholesterol-absorption-inhibitory action of pea protein by miniaturizing the particle diameter of pea protein.

This invention belongs to the fields of biomedical materials and colloid chemistry, and discloses a structurally remodeled egg yolk low-density lipoprotein biomimetic liposome and its application in regulating cholesterol metabolism. The method includes extracting and purifying natural egg yolk low-density lipoprotein; selectively removing endogenous cholesterol by adding β-cyclodextrin under alkaline conditions; adding a phytosterol ethanol solution to the cholesterol-removed low-density lipoprotein dispersion, followed by incubation and dialysis purification to obtain the biomimetic liposome. The obtained biomimetic liposome uses partially cholesterol-removed egg yolk low-density lipoprotein as its structural framework, with phytosterols embedded in its phospholipid monolayer and lipid core interface. This biomimetic liposome can inhibit cholesterol micelle formation, reduce cholesterol absorption, promote macrophage cholesterol efflux, and inhibit macrophage foam formation. It can be used to prepare cholesterol metabolism regulating materials, functional delivery systems, and dietary supplement products.

The invention provides sterol cream capable of blocking cholesterol absorption as well as a preparation method and application of the sterol cream, and belongs to the technical field of foods. The sterol cream provided by the invention is prepared from the following raw materials in parts by weight: 20 to 200 parts of cheese, 50 to 500 parts of unsalted butter, 25 to 250 parts of milk and 10 to 100 parts of sterol. The sterol is beta-sitosterol and / or stigmasterol. The invention also provides a preparation method of the cream, and the cholesterol blocking agent is reasonably added, so that the cream has the effect of reducing the risk of cardiovascular diseases under the condition that the taste, the texture and the flavor of the cream are not different from those of common cream, and the cream has rich milk flavor and a good baking function. The cream is free of essence, pigment and preservative, is low in manufacturing cost and easy to operate, and has a good market prospect.

The invention discloses targeted prebiotic plant extraction dietary powder for conditioning hyperlipidemia and a preparation process of the targeted prebiotic plant extraction dietary powder. In the invention, patent strains such as lactobacillus plantarum LP-12, bifidobacterium longum BL-08 and the like in the formula can regulate intestinal flora balance and inhibit activity of liver cholesterol synthesis key enzymes, so that generation of endogenous cholesterol is reduced from the source; natural monacolin K and phytosterol ester in the red yeast rice powder respectively inhibit cholesterol synthesis and competitively block exogenous cholesterol absorption to form a bidirectional regulation mechanism. Meanwhile, the oat beta-glucan forms an adhesive layer in the intestinal tract, so that part of lipid absorption is physically blocked; and prebiotics such as resistant dextrin and fructo-oligosaccharide provide nutrients for probiotics, promote secretion of short-chain fatty acids and further activate lipid metabolism related pathways. The components cooperate with one another to cover the whole chain of cholesterol synthesis, absorption and metabolism, so that the multi-dimensional lipid-lowering effect of'source inhibition-process blocking-metabolic regulation 'is realized.

The invention belongs to the technical field of health-care foods, and particularly relates to a health-care food for assisting in regulating blood fat, blood pressure and blood sugar and a preparation method of the health-care food. A multistage pellet system is constructed by utilizing a phytosterol solid dispersion system, a nitrate-citrulline slow release system and a propionate-fermented fiber colon targeting system. Phytosterol is rapidly dissolved out of the pellet A at the upper section of the stomach and intestine, cholesterol absorption is competed, and the intestinal mucosa environment is optimized; the pellet B slowly releases beet nitrate and L-citrulline in the small intestine, and NO is stably supplied to improve vasodilation; the pellet C releases propionate and fermented fiber in a targeted manner through the colon, regulates blood sugar through short-chain fatty acid and reversely enhances an NO pathway, so that bidirectional synergy is realized; besides, the conflict of hydrophilic and hydrophobic components is eliminated through the HPMC-PVP co-loaded solid dispersion, the crosslinking degree of alginate gel beads and the loading proportion of propionate are controlled to avoid acidic interference, the bioavailability of active components is remarkably improved, and dynamic synergistic regulation of blood fat, blood pressure and blood sugar is achieved.

The present application belongs to the technical field of feed additive, and particularly relates to a compound fatty acid preparation for promoting chicken growth, and a preparation method and application thereof. The compound fatty acid preparation for promoting chicken growth is mainly composed of the following raw materials in parts by weight: 3-6 parts of stigmasterol, 2-4 parts of campesterol, 10-20 parts of linoleic acid, 12-24 parts of tributyrin, 1-2 parts of emulsifier, 3-5 parts of soybean phospholipid, 3-5 parts of protective agent, and 30-80 parts of water. The combination of stigmasterol and campesterol can significantly improve the targeted release efficiency of linoleic acid and tributyrin. The released butyric acid can activate the mitochondrial beta-oxidation pathway of intestinal epithelial cells, significantly improve the efficiency of tricarboxylic acid cycle, and enhance the intestinal barrier function. The phytosterol can also competitively inhibit the NPC1L1 transporter, reduce the intestinal cholesterol absorption, direct the energy to the growth demand, thereby improving the daily weight gain of broilers and reducing the feed-meat ratio.

The invention relates to the technical field of feed additives, in particular to a feed regulating agent for reducing egg cholesterol, which comprises the following components in parts by mass: 8-12 parts of phytosterol ester; 5 to 8 parts of chitosan oligosaccharide; 15 to 20 parts of soybean lecithin; 3-5 parts of tea polyphenol; 3-5 parts of choline chloride; 2 to 4 parts of soy isoflavone; 5-10 parts of inulin; 1 to 2 parts of inositol; 2 to 3 parts of compound probiotics; and 30-50 parts of a carrier. According to the scheme, the cholesterol is further reduced by about 10% compared with the prior art by utilizing a cholesterol absorption mechanism from the perspective of blocking cholesterol absorption through component synergy, and the cholesterol content is only about 60% of that of normally bred and produced eggs.

The invention belongs to the technical field of bioactive peptides and medicines, and discloses a bioactive peptide composition with a blood fat reducing effect and application thereof.The composition comprises a first peptide component A and a second peptide component B. The first peptide component A is a low-molecular-weight peptide component derived from soybean protein enzymolysis products, and the second peptide component B is a low-molecular-weight peptide component derived from soybean protein enzymolysis products. The second peptide component B is a medium-low molecular weight peptide component derived from a walnut meal proteolysis product, and the second peptide component B and the second peptide component B are compounded according to a specific mass ratio to form the synergistic blood fat reducing composition. Through differential dipeptide component design, the synergistic effect on cholesterol absorption and lipid metabolism regulation is achieved, and the composition has a good blood fat reducing effect and can be used for preparing related products for regulating blood fat, improving lipid metabolism and assisting in preventing or improving hyperlipemia.